New study finds that reduced hepatic adenosine kinase expression (ADK) raises the susceptibility to the acute toxic effects of a carcinogen. Low ADK in the liver might be a risk factor and biomarker for the development of cancer. The findings of the study are published in the Journal of Caffeine and Adenosine Research.
Combined results from the study of human liver cancer samples and mice with reduced levels of ADK expression support these findings.
In the article entitled "Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen," Rkia El-Kharrag, Ph.D., Randy Owen, BSc, and Detlev Boison, Ph.D., Legacy Research Institute, Portland, OR, showed that 64% of patients with liver cancer had lower ADK expression.
"These results might represent a very significant advance in the field. Further studies should confirm if adenosine kinase represents a new biomarker or a pharmacological target in liver cancer," says Editor-in-Chief of Journal of Caffeine and Adenosine Research Sergi Ferré, MD, PhD, and his research colleagues in the Integrative Neurobiology Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD.